SW480 |
Growth inhibition assay |
20 uM |
48 hrs |
Reversal of growth inhibition of human SW480 cells at 20 uM after 48 hrs by MTS assay in presence of >50 uM mevalonate |
17472962 |
SW480 |
Function assay |
20 uM |
48 hrs |
Decrease in survivin expression in human SW480 cells at 20 uM after 48 hrs by immunoblot analysis |
17472962 |
SW480 |
Function assay |
20 uM |
48 hrs |
Reversal of reduction in survivin expression in human SW480 cells at 20 uM after 48 hrs by immunoblot analysis in presence of 100 uM mevalonate |
17472962 |
SW480 |
Function assay |
20 uM |
48 hrs |
Reversal of reduction in survivin mRNA expression in human SW480 cells at 20 uM after 48 hrs by RT-PCR technique in presence of 100 uM mevalonate |
17472962 |
SW480 |
Growth inhibition assay |
20 uM |
48 hrs |
Reversal of growth inhibition of human SW480 cells at 20 uM after 48 hrs by immunoblot analysis in presence of farnesyl pyrophosphate |
17472962 |
SW480 |
Growth inhibition assay |
20 uM |
48 hrs |
Reversal of growth inhibition of human SW480 cells at 20 uM after 48 hrs by immunoblot analysis in presence of geranylgeranyl pyrophosphate |
17472962 |
SW480 |
Function assay |
20 uM |
48 hrs |
Decrease in isoprenylated Ras level in human SW480 cells at 20 uM after 48 hrs by immunoblot analysis |
17472962 |
SW480 |
Function assay |
20 uM |
48 hrs |
Reversal of decrease in isoprenylated Ras level in human SW480 cells at 20 uM after 48 hrs by immunoblot analysis in presence of mevalonate |
17472962 |
SW480 |
Function assay |
20 uM |
48 hrs |
Reversal of decrease in isoprenylated Ras level in human SW480 cells at 20 uM after 48 hrs by immunoblot analysis in presence of farnesyl pyrophosphate |
17472962 |
SW480 |
Function assay |
20 uM |
48 hrs |
Reversal of decrease in isoprenylated Ras level in human SW480 cells at 20 uM after 48 hrs by immunoblot analysis in presence of geranylgeranyl pyrophosphate |
17472962 |
MDA-MB-231 |
Function assay |
1 to 10 uM |
24 hrs |
Induction of p21 expression in human PR, ER, HER2-negative human MDA-MB-231 cells at 1 to 10 uM after 24 hrs by western blot analysis |
24556504 |
MDA-MB-231 |
Growth inhibition assay |
>10 uM |
48 hrs |
Total growth inhibition of PR, ER, HER2-negative human MDA-MB-231 cells at >10 uM after 48 hrs by WST-1 assay |
24556504 |
RPMI-8226 |
Function assay |
10 uM |
48 hrs |
Inhibition of HMG-coA reductase in human RPMI-8226 cells assessed as disruption of Rap1a geranylgeranylation at 10 uM after 48 hrs by western blot analysis |
24726306 |
HepG2 |
Function assay |
1 uM |
6 hrs |
Lipid-lowering effect in human HepG2 cells assessed as reduction in oleic acid-induced lipid accumulation at 1 uM after 6 hrs by oil-red O staining based spectrophotometry |
25304895 |
HepG2 |
Function assay |
10 uM |
24 hrs |
Lipid-lowering effect in human HepG2 cells assessed as reduction in oleic acid-induced total cholesterol accumulation at 10 uM after 24 hrs by oil-red O staining based spectrophotometry |
25304895 |
HepG2 |
Function assay |
10 uM |
24 hrs |
Lipid-lowering effect in human HepG2 cells assessed as reduction in oleic acid-induced triglyceride accumulation at 10 uM after 24 hrs by oil-red O staining based spectrophotometry |
25304895 |
RPMI8226 |
Apoptosis assay |
20 uM |
48 hrs |
Induction of apoptosis in human RPMI8226 cells assessed as increase in PARP cleavage at 20 uM incubated for 48 hrs by immunoblot method |
25935643 |
RPMI8226 |
Apoptosis assay |
20 uM |
48 hrs |
Induction of apoptosis in human RPMI8226 cells assessed as increase in caspase-3 cleavage at 20 uM incubated for 48 hrs by immunoblot method |
25935643 |
MDA-MB-231 |
Function assay |
30 uM |
24 hrs |
Induction of reactive oxygen species in human MDA-MB-231 cells at 30 uM after 24 hrs by DCFH-DA probe-based flow cytometric method |
27756564 |
MDA-MB-231 |
Function assay |
10 uM |
6 to 24 hrs |
Induction of CHK1/2 phosphorylation in human MDA-MB-231 cells assessed as increase in p53 phosphorylation at 10 uM after 6 to 24 hrs by Western blot method |
27756564 |
MDA-MB-231 |
Function assay |
10 uM |
6 to 24 hrs |
Induction of ATM phosphorylation in human MDA-MB-231 cells at 10 uM after 6 to 24 hrs by Western blot method |
27756564 |
RPMI8226 |
Function assay |
0.5 uM |
48 hrs |
Inhibition of FTase in human RPMI8226 cells assessed as disruption of H-ras farnesylation at 0.5 uM after 48 hrs by immunoblot analysis |
31699606 |
RPMI8226 |
Function assay |
0.5 uM |
48 hrs |
Inhibition of GGtase-1 in human RPMI8226 cells assessed as disruption of Rap1a geranylgeranylation at 0.5 uM after 48 hrs by immunoblot analysis |
31699606 |
LS180 |
Function assay |
20 uM |
|
Inhibition of survivin expression in parent human LS180 cells at 20 uM by immunoblot analysis |
17472962 |
LS180 |
Function assay |
20 uM |
|
Inhibition of survivin expression in survivin gene transfected human LS180 cells at 20 uM immunoblot analysis |
17472962 |
SW480 |
Function assay |
20 uM |
|
Inhibition of FBS-stimulated increase in Ras protein expression in human SW480 cells assessed as GTP-bound protein at 20 uM by immunoblot analysis |
17472962 |
SW480 |
Function assay |
20 uM |
|
Reversal of inhibition of FBS-stimulated increase in Ras protein expression in human SW480 cells assessed as GTP-bound protein at 20 uM by immunoblot analysis |
17472962 |
SW480 |
Function assay |
20 uM |
|
Inhibition of FBS-stimulated increase in Akt phosphorylation in human SW480 cells at 20 uM by immunoblot analysis |
17472962 |
Neuro2a |
Function assay |
1 uM |
|
Inhibition of HMGCoA reductase in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis |
26789657 |
SW480 |
Growth inhibition assay |
|
96 hrs |
Growth inhibition of human SW480 cells after 96 hrs by MTS assay, IC50=7.1μM. |
17472962 |
Huh-7/3-1 |
Antiviral assay |
|
72 hrs |
Antiviral activity against Hepatitis C virus (isolate Con1) genotype 1b in human Huh-7/3-1 cells assessed as inhibition of HCV replication after 72 hrs by luciferase assay |
16408072 |
LS180 |
Growth inhibition assay |
|
96 hrs |
Growth inhibition of human LS180 cells after 96 hrs by MTS assay, IC50=25.3μM. |
17472962 |
HT29 |
Growth inhibition assay |
|
96 hrs |
Growth inhibition of human HT29 cells after 96 hrs by MTS assay, IC50=46.8μM. |
17472962 |
LS180 |
Growth inhibition assay |
|
72 hrs |
Blockade of growth inhibition of human LS180 cells after 72 hrs by MTS method |
17472962 |
K562 |
Function assay |
|
48 hrs |
Inhibition of GGTase1 in human K562 cells assessed as reduction of Rap1a protein geranylgeranylation after 48 hrs by Western blotting |
20832326 |
A549 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50=11.4μM. |
23570542 |
A549 |
Function assay |
|
5 mins |
Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis, IC50=19.8μM. |
23570542 |
HS68 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human HS68 cells after 72 hrs by MTT assay, IC50=23.2μM. |
23570542 |
MEF |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay, IC50=35μM. |
23570542 |
MDA-MB-361 |
Growth inhibition assay |
|
48 hrs |
Growth inhibition of ER-positive, HER2-positive human MDA-MB-361 cells after 48 hrs by WST-1 assay |
24556504 |
MDA-MB-468 |
Growth inhibition assay |
|
48 hrs |
Total growth inhibition of PR, ER, HER2-negative human MDA-MB-468 cells after 48 hrs by WST-1 assay |
24556504 |
AU565 |
Growth inhibition assay |
|
48 hrs |
Growth inhibition of ER-negative, HER2-positive human AU565 cells after 48 hrs by WST-1 assay |
24556504 |
MCF7 |
Growth inhibition assay |
|
48 hrs |
Total growth inhibition of ER-positive, HER2-negative human MCF7 cells after 48 hrs by WST-1 assay |
24556504 |
HepG2 |
Function assay |
|
6 hrs |
Lipid lowering activity in human HepG2 cells assessed as decrease in oleic acid elicited lipid accumulation after 6 hrs by oil-red O staining method, IC50=8.3μM. |
26169125 |
A549 |
Antiviral assay |
|
48 hrs |
Antiviral activity against Dengue virus 2 NGC infected in human A549 cells assessed as reduction in virus replication after 48 hrs by renilla luciferase reporter gene assay, EC50=1.82μM. |
26771861 |
PC3 |
Cytotoxicity assay |
|
48 hrs |
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay, IC50=5.4μM. |
27756564 |
HEK293 |
Function assay |
|
|
TP_TRANSPORTER: inhibition of estradiol-17beta-glucuronide uptake(estradiol-17beta-glucuronide:0.02uM) in OATP1B1-expressing HEK293 cells, IC50=28μM. |
15616150 |
MDCK |
Function assay |
|
|
TP_TRANSPORTER: inhibition of calcein-AM efflux in MDR1-expressing MDCK cells, IC50=10μM. |
15616150 |
NIH-3T3-G185 |
Function assay |
|
|
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells, IC50=32.7μM. |
11716514 |
3T3-G185 |
Function assay |
|
|
TP_TRANSPORTER: inhibition of Daunorubicin transport in 3T3-G185 cells, IC50=26μM. |
11474784 |
HEP-G2 |
Function assay |
|
|
Tested for ability to inhibit incorporation of [14C]acetate into cholesterol in cultured human hepatoma (HEP-G2) cells; 0.061-0.10, IC50=0.079μM. |
8246237 |
HEP G2 |
Function assay |
|
|
Tested for inhibition of cholesterol biosynthesis in HEP G2 cells, IC50=0.029μM. |
7932551 |
HEP G2 |
Function assay |
|
|
Inhibition of cellular HMG-CoA reductase in cultures of human HEP G2 cells, determined by decreased incorporation of sodium [14C]acetate into cholesterol., IC50=0.05μM. |
2296036 |
HEP G2 |
Function assay |
|
|
Inhibition of cellular HMG-CoA reductase in cultures of hepatic cells (HEP G2, a human hepatoma cell line), IC50=0.00005μM. |
2153213 |
HEP G2 |
Function assay |
|
|
Inhibition of the incorporation of sodium [14C]acetate into cholesterol in HEP G2 cells., IC50=0.05μM. |
1656041 |
HES 9 cell line |
Function assay |
|
|
Concentration required to inhibit HMG-CoA reductase by 50% was determined in HES 9 cell line, IC50=0.013 μM |
1527791 |
Vero |
Cytotoxicity assay |
|
|
Cytotoxicity against African green monkey Vero cells, IC50=2.2μM. |
27228159 |
KB |
Cytotoxicity assay |
|
|
Cytotoxicity against human KB cells by resazurin microplate assay, IC50=15.6μM. |
27228159 |
DAOY |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells |
29435139 |
SJ-GBM2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells |
29435139 |
BT-12 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells |
29435139 |
Rh18 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells |
29435139 |
A549 |
Function assay |
|
|
Reductase Activity Assay: The HMGR activity was performed using HMG-CoA reductase assay kit from Sigma-Aldrich with the human recombinant protein or 100 μg total cell lysates from A549 cells. Lovastatin was used as a positive control, IC50=0.0295μM. |
ChEMBL |
HepG2 |
Function assay |
|
|
Compound was evaluated for inhibitory activity against HMG-CoA reductase in HepG2 cells, IC50=0.039μM. |
ChEMBL |